PARP Inhibitors in Cancer Diagnosis and Therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Poly (ADP-ribose) polymerase (PARP) enzyme targeting is a key therapeutic strategy for cancers with homologous recombination deficiencies.
• PARP inhibitors (PARPi) are currently used for BRCA-mutated cancers, showing improved outcomes as single agents across various cancer types.
• Combination therapies involving PARPi are being explored to enhance patient responses through drug synergism.

Purpose of the Study:

• To review the development and clinical application of PARPi in diverse cancer types, from preclinical studies to clinical trials.
• To provide an overview of PARP imaging agents for cancer therapy.
• To discuss the potential of radiolabeled PARPi as radionuclide therapies.

Main Methods:

• Review of preclinical models and clinical trial data on PARPi efficacy.
• Analysis of current literature on PARP imaging agents.
• Exploration of the role of radiolabeled PARPi in radionuclide therapy.

Main Results:

• PARPi demonstrate efficacy in various cancer types, particularly those with BRCA mutations.
• Patient selection for PARPi monotherapy or combination therapy is challenging due to variable responses and acquired resistance.
• PARP imaging agents and radiolabeled PARPi represent emerging therapeutic and diagnostic modalities.

Conclusions:

• Optimizing patient selection is crucial for maximizing the benefits of PARPi therapy.
• Combination therapies and novel applications like PARP imaging and radionuclide therapy hold significant promise for advancing cancer treatment.
• Further research is needed to overcome resistance mechanisms and refine patient stratification strategies for PARPi.